Search
Search Results
-
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
BackgroundProgesterone receptor (PR)-negative tumors have been shown to have worse prognosis and were underrepresented in recent trials on patients...
-
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13–22% of breast cancers (BC). Approximately 60–70% of HER2+ BC co-express...
-
Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancer
Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and...
-
Therapeutic Efficacy of Estrogen-Related Receptor β in Breast Carcinoma
Breast cancer mortality is fleeting in females worldwide. Numerous genetic, epigenetic, and environmental factors contribute to breast cancer...
-
Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients
Estrogen receptor-positive (ER+) breast cancer generally confers a more favorable prognosis than ER-negative cancer, however, a different picture is...
-
Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
PurposeSex-steroid hormones are associated with postmenopausal breast cancer but potential confounding from other biological pathways is rarely...
-
Nanomedicine in therapeutic warfront against estrogen receptor–positive breast cancer
Breast cancer (BC) is the most frequently diagnosed malignancy in women worldwide. Almost 70–80% of cases of BC are curable at the early...
-
Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status
BackgroundAlthough several transcriptome-wide association studies (TWASs) have been performed to identify genes associated with overall breast cancer...
-
Association of H3K9me3 with breast cancer prognosis by estrogen receptor status
BackgroundCellular experiments revealed that a decreased histone H3 lysine 9 trimethylation (H3K9me3) level was associated with the upregulation of...
-
Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway
Chemotherapy can improve the prognosis and overall survival of breast cancer patients, but chemoresistance continues a major problem in clinical....
-
Therapeutic Efficacy of Estrogen-Related Receptor β in Breast Carcinoma
Breast cancer mortality is fleeting in females worldwide. Numerous genetic, epigenetic, and environmental factors contribute to breast cancer...
-
Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment
Tumor heterogeneity affects diagnosis, prognosis and response to therapy. Heterogeneity is found in both normal and neoplastic human mammary gland....
-
Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
BackgroundDespite numerous studies on racial/ethnic disparities among patients with breast cancer, there is a paucity of literature evaluating...
-
Small molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance
IntroductionEstrogen receptor (ER) positive patients compromise about 70% of breast cancers. Tamoxifen, an antagonist of ERα66 (the classic ER), is...
-
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases
TP53 and estrogen receptor (ER) are essential in breast cancer development and progression, but TP53 status (by DNA sequencing or protein expression)...
-
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
Circulating IL-6, an activator of JAK/STAT signaling, is associated with poor prognosis and aromatase inhibitor (AI) resistance in hormone-receptor...
-
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers
BackgroundOther than for breast cancer, endocrine therapy has not been highly effective for gynecologic cancers. Endocrine therapy resistance in...
-
The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
BackgroundCurrently, the value of oral selective estrogen receptor degraders (SERDs) for hormone receptor-positive (HR+) and human epidermal growth...
-
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
The ESR1 ligand binding domain activating mutations are the most prevalent genetic mechanism of acquired endocrine resistance in metastatic hormone...
-
Endogenous estrogen receptor modulating oxysterols and breast cancer prognosis: Results from the MARIE patient cohort
Background27-hydroxycholesterol (HC) and 25-HC were identified as endogenous selective estrogen receptor modulators (SERMs) and estrogen receptor...
